초록 ▼

Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present inventi

Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.

대표청구항 ▼

What is claimed is: 1. A chimeric peptide for stimulating an immune response to HER-2 protein, wherein said chimeric peptide comprises a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining said HER-2 B cell epitope to said Th epitope, wherein the sequence of the HER-2 B cell epitope

What is claimed is: 1. A chimeric peptide for stimulating an immune response to HER-2 protein, wherein said chimeric peptide comprises a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining said HER-2 B cell epitope to said Th epitope, wherein the sequence of the HER-2 B cell epitope is SEQ ID NO: 6, wherein the Th epitope comprises a sequence selected from the group consisting of: N-S-V-D-D-A-L-I-N-S-T-I-Y-S-Y-F-P-S-V, SEQ. ID. NO: 13; P-G-I-N-G-K-A-I-H-L-V-N-N-Q-S-S-E, SEQ ID NO: 14; Q-Y-I-K-A-N-S-K-F-I-G-I-T-E-L, SEQ ID NO: 15; F-N-N-F-T-V-S-F-W-L-R-V-P-K-V-S-A-S-H-L-E, SEQ ID NO: 16; L-S-E-I-K-G-V-I-V-H-R-L-E-G-V, SEQ ID NO: 17; F-F-L-L-T-R-I-L-T-I-P-Q-S-L-N, SEQ ID NO: 18; and T-C-G-V-G-V-R-V-R-S-R-V-N-A-A-N-K-K-P-E, SEQ ID NO: 19; and wherein the linker consists of from one to fifteen amino acids. 2. An immunogenic composition comprising the chimeric peptide of claim 1, further comprising a second chimeric peptide wherein said second chimeric peptide comprises a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining said HER-2 B cell epitope to said Th epitope; wherein the sequence of the HER-2 B cell epitope is SEQ ID NO: 42, wherein the Th epitope comprises a sequence selected from the group consisting of: N-S-V-D-D-A-L-I-N-S-T-I-Y-S-Y-F-P-S-V, SEQ. ID. NO: 13; P-G-I-N-G-K-A-I-H-L-V-N-N-Q-S-S-E, SEQ ID NO: 14; Q-Y-I-K-A-N-S-K-F-I-G-I-T-E-L, SEQ ID NO: 15; F-N-N-F-T-V-S-F-W-L-R-V-P-K-V-S-A-S-H-L-E, SEQ ID NO: 16; L-S-E-I-K-G-V-I-V-H-R-L-E-G-V, SEQ ID NO: 17; F-F-L-L-T-R-I-L-T-I-P-Q-S-L-N, SEQ ID NO: 18; and T-C-G-V-G-V-R-V-R-S-R-V-N-A-A-N-K-K-P-E, SEQ ID NO: 19; and wherein the linker consists of from one to fifteen amino acids. 3. An immunogenic composition comprising the chimeric peptide of claim 1, further comprising a second chimeric peptide wherein said second chimeric peptide comprises a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining said HER-2 B cell epitope to said Th epitope; wherein SEQ ID NO: 42 is the sequence of the HER 2-B cell epitope, wherein SEQ ID NO: 17 is the sequence of the Th epitope, and wherein SEQ ID NO: 20 is the sequence of the linker. 4. A chimeric peptide for stimulating an immune response to HER-2 protein, wherein said chimeric peptide comprises a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining said HER-2 B cell epitope to said Th epitope; wherein SEQ ID NO: 6 is the sequence of the HER 2-B cell epitope, wherein SEQ ID NO: 17 is the sequence of the Th epitope, and wherein SEQ ID NO: 20 is the sequence of the linker. 5. An immunogenic composition comprising the chimeric peptide of claim 4, further comprising a second chimeric peptide wherein said second chimeric peptide comprises a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining said HER-2 B cell epitope to said Th epitope; wherein the sequence of the HER-2 B cell epitope is SEQ ID NO: 42, wherein the Th epitope comprises a sequence selected from the group consisting of: N-S-V-D-D-A-L-I-N-S-T-I-Y-S-Y-F-P-S-V, SEQ. ID. NO: 13; P-G-I-N-G-K-A-I-H-L-V-N-N-Q-S-S-E, SEQ ID NO: 14; Q-Y-I-K-A-N-S-K-F-I-G-I-T-E-L, SEQ ID NO: 15; F-N-N-F-T-V-S-F-W-L-R-V-P-K-V-S-A-S-H-L-E, SEQ ID NO: 16; L-S-E-I-K-G-V-I-V-H-R-L-E-G-V, SEQ ID NO: 17; F-F-L-L-T-R-I-L-T-I-P-Q-S-L-N, SEQ ID NO: 18; and T-C-G-V-G-V-R-V-R-S-R-V-N-A-A-N-K-K-P-E, SEQ ID NO: 19; and wherein the linker consists of from one to fifteen amino acids. 6. An immunogenic composition comprising the chimeric peptide of claim 4, further comprising a second chimeric peptide wherein said second chimeric peptide comprises a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining said HER-2 B cell epitope to said Th epitope; wherein SEQ ID NO: 42 is the sequence of the HER 2-B cell epitope, wherein SEQ ID NO: 17 is the sequence of the Th epitope, and wherein SEQ ID NO: 20 is the sequence of the linker.